Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

MERCK & CO., INC.

(MRK)
  Report
Delayed Nyse  -  04:03 2022-10-06 pm EDT
87.44 USD   -1.07%
08:19aMarketScreener's World Press Review : October 7, 2022
MS
08:11aMerck and Ridgeback Biotherapeutics Provide Update on New Clinical and Non-Clinical Studies of LAGEVRIO
AQ
10/06Merck & Co.'s COVID-19 Pill Fails to Cut Hospitalization, Death in UK Study
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck's Diabetes Drug Januvia Found to Contain Potential Carcinogen; Shares Briefly Slide Into Negative Territory

08/09/2022 | 02:52pm EDT


© MT Newswires 2022
All news about MERCK & CO., INC.
08:19aMarketScreener's World Press Review : October 7, 202..
MS
08:11aMerck and Ridgeback Biotherapeutics Provide Update on New Clinical and Non-Clinical Stu..
AQ
10/06Merck & Co.'s COVID-19 Pill Fails to Cut Hospitalization, Death in UK Study
MT
10/06Merck and Ridgeback Biotherapeutics Provide Update on New Clinical and Non-Clinical Stu..
BU
10/06Merck and Ridgeback Biotherapeutics Provide Update on New Clinical and Non-Clinical Stu..
CI
10/06Ultimovacs' Cancer Vaccine Prolongs Patient Survival In Early-stage Study
MT
10/05GSK's Lung Cancer Combination Therapy Shows Shrunken Tumors In Mid-stage Study
MT
10/04NextCure Begins Phase 1b/2 Trial to Study NC410, Keytruda Combination to Treat Solid Tu..
MT
10/03NetScientific Shares Rise After FDA Meeting on HPV Carcinoma Therapy
DJ
09/29U.S. Court of Appeals for the Federal Circuit Rules in Favor of Merck in Sitagliptin Di..
BU
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2022 58 621 M - -
Net income 2022 15 200 M - -
Net Debt 2022 18 009 M - -
P/E ratio 2022 14,1x
Yield 2022 3,24%
Capitalization 222 B 222 B -
EV / Sales 2022 4,09x
EV / Sales 2023 4,04x
Nbr of Employees 67 500
Free-Float 70,7%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 87,44 $
Average target price 100,00 $
Spread / Average Target 14,4%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Dave Williams EVP, Chief Information & Digital Officer
Lisa LeCointe-Cephas Chief Ethics & Compliance Officer, SVP
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.14.09%221 510
JOHNSON & JOHNSON-5.35%425 691
ELI LILLY AND COMPANY20.11%316 361
ROCHE HOLDING AG-14.13%271 357
ABBVIE INC.3.61%248 046
PFIZER, INC.-25.28%241 836